Irritable bowel syndrome (IBS) causes bouts of stomach cramps, diarrhea, bloating or constipation, where it is a common and long-term condition of the digestive systems. The symptoms of this syndrome vary according to individuals and can last from few days to a few months at a time. It is also observed during stress or after eating certain food. It is a gastrointestinal disorder of the gut that is characterized by colon muscle contractions that mainly affects the large intestine. It is mainly observed in elderly people.
Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/506
It is diagnosed by performing blood tests and endoscopy. As this syndrome is not completely curable, the symptoms can be managed using medicines. Irritable bowel syndrome treatment market is underpenetrated and in the nascent stage. Various investigations are carried out to rule out conditions such as stool microscopy and culture to exclude infectious conditions, blood test like full blood examination, erythrocyte sedimentation, liver function tests and serological testing, abdominal ultrasound is carried out to rule out gallstones and other biliary tract diseases, endoscopy and biopsies to exclude inflammatory bowel disease and hydrogen breath testing to exclude fructose and lactose malabsorption.
By Disease Type
- IBS With Constipation
- IBS With Diarrhea
- IBS With Alternating Constipation and Diarrhea
By End User
- Homecare Settings
Request a Customization: https://www.coherentmarketinsights.com/insight/request-customization/506
Rise in novel therapeutic classes fuels growth of the irritable bowel syndrome treatment market
As of 2016, there are only 2 medications approved by Food Drug Administration (FDA) for irritable bowel syndrome, namely Alosetron (Lotronex) and Lubiprostone (Amitiza) and both these medications are proved right only in women in the U.S. LINZESS is FDA approved to treat IBS with constipation in both men and women, while in Japan, Irribow drug (ramosetron) is available. Due lack of drugs with safety and efficacy there is weak competition between manufacturers. However, the market scenario is expected to change after the launch of new disease treatment medications. Rifaximin (Xifaxan) is an antibiotic approved in May 2015 by FDA in the U.S. for treatment of IBS with diarrhea in adults. According to International Foundation for Functional Gastrointestinal Disorders, Inc. (IFFGD) new prescription drugs are being studied currently but have not yet approved by FDA for treatment. Drugs for IBS with constipation are currently in third phase of clinical trials that include plecanatide, and elobixibat which is a first-in-class compound. These new drugs are expected to show rise in irritable bowel syndrome treatment market in the near future.
Asia Pacific to be Growth Engine of the Irritable Bowel Syndrome Treatment Market
Irritable bowel syndrome treatment is segmented geographically into North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. New drugs with improved efficacy which provide relief to irritable bowel syndrome and increase in awareness regarding chronic nature of the syndrome favors the growth of irritable bowel syndrome treatment market in Asia-Pacific. Most of the drugs are approved only for the U.S., making it the key geographic region for irritable bowel market. Europe also favors the market due to rising incidence of irritable bowel syndrome in the region.
To know the latest trends and insights prevalent in the Irritable Bowel Syndrome Treatment Market, click the link below: https://www.coherentmarketinsights.com/ongoing-insight/irritable-bowel-syndrome-treatment-market-506
Key players operating in irritable bowel syndrome treatment market
Key players in irritable bowel syndrome treatment market include Sucampo Pharmaceuticals, Inc., Ironwood Pharmaceuticals, valeant Pharmaceuticals International Inc., Lexicon Pharmaceuticals, Abbott Laboratories, Salix Pharmaceuticals, Inc., Allergan Plc and GlaxoSmithKline plc.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.
Coherent Market Insights
1001 4th Ave,
Seattle, WA 98154
Follow Our Company Page on Linkedin @ https://www.linkedin.com/company/coherent-market-insights